KR20150018647A - 신규의 나프록센 제제 - Google Patents

신규의 나프록센 제제 Download PDF

Info

Publication number
KR20150018647A
KR20150018647A KR1020157002594A KR20157002594A KR20150018647A KR 20150018647 A KR20150018647 A KR 20150018647A KR 1020157002594 A KR1020157002594 A KR 1020157002594A KR 20157002594 A KR20157002594 A KR 20157002594A KR 20150018647 A KR20150018647 A KR 20150018647A
Authority
KR
South Korea
Prior art keywords
milling
less
dosage form
sodium
unit dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157002594A
Other languages
English (en)
Korean (ko)
Inventor
아론 도드
펠릭스 메이서
마크 노레트
에이드리언 러셀
에이치. 윌리엄 보쉬
Original Assignee
아이슈티카 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43010610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150018647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2009901748A external-priority patent/AU2009901748A0/en
Application filed by 아이슈티카 피티와이 리미티드 filed Critical 아이슈티카 피티와이 리미티드
Publication of KR20150018647A publication Critical patent/KR20150018647A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
KR1020157002594A 2009-04-24 2010-04-23 신규의 나프록센 제제 Ceased KR20150018647A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17229109P 2009-04-24 2009-04-24
US61/172,291 2009-04-24
AU2009901748A AU2009901748A0 (en) 2009-04-24 A Novel Formulation of Diclofenac
AU2009901748 2009-04-24
PCT/AU2010/000471 WO2010121327A1 (en) 2009-04-24 2010-04-23 A novel formulation of diclofenac

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117027888A Division KR20120029398A (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형

Publications (1)

Publication Number Publication Date
KR20150018647A true KR20150018647A (ko) 2015-02-23

Family

ID=43010610

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020157002594A Ceased KR20150018647A (ko) 2009-04-24 2010-04-23 신규의 나프록센 제제
KR1020157018881A Expired - Fee Related KR101580656B1 (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형
KR1020147028068A Ceased KR20140124873A (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형
KR1020117027888A Ceased KR20120029398A (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형
KR1020167036214A Abandoned KR20170002683A (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020157018881A Expired - Fee Related KR101580656B1 (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형
KR1020147028068A Ceased KR20140124873A (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형
KR1020117027888A Ceased KR20120029398A (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형
KR1020167036214A Abandoned KR20170002683A (ko) 2009-04-24 2010-04-23 디클로페낙의 신규 제형

Country Status (23)

Country Link
US (12) US8735450B2 (cg-RX-API-DMAC7.html)
EP (2) EP3290030A1 (cg-RX-API-DMAC7.html)
JP (2) JP6222924B2 (cg-RX-API-DMAC7.html)
KR (5) KR20150018647A (cg-RX-API-DMAC7.html)
CN (5) CN102438610A (cg-RX-API-DMAC7.html)
AP (2) AP2015008933A0 (cg-RX-API-DMAC7.html)
AU (1) AU2010239080B2 (cg-RX-API-DMAC7.html)
CA (1) CA2759123C (cg-RX-API-DMAC7.html)
CO (1) CO6470810A2 (cg-RX-API-DMAC7.html)
DK (1) DK2421525T3 (cg-RX-API-DMAC7.html)
EA (1) EA201171285A1 (cg-RX-API-DMAC7.html)
HK (2) HK1202061A1 (cg-RX-API-DMAC7.html)
IL (1) IL215869B (cg-RX-API-DMAC7.html)
MA (1) MA33295B1 (cg-RX-API-DMAC7.html)
MX (2) MX337619B (cg-RX-API-DMAC7.html)
MY (1) MY168079A (cg-RX-API-DMAC7.html)
NZ (3) NZ710383A (cg-RX-API-DMAC7.html)
PH (1) PH12015500301B1 (cg-RX-API-DMAC7.html)
SG (2) SG175314A1 (cg-RX-API-DMAC7.html)
TN (1) TN2011000543A1 (cg-RX-API-DMAC7.html)
UA (1) UA106232C2 (cg-RX-API-DMAC7.html)
WO (1) WO2010121327A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108650B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
CA2759109A1 (en) 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
CA2759123C (en) * 2009-04-24 2019-01-15 Iceutica Pty Ltd Compositions of diclofenac acid with improved dissolution
KR20160148041A (ko) * 2009-04-24 2016-12-23 아이슈티카 피티와이 리미티드 캅셀화된 나노입자의 상업적 규모의 생산
AP2015008965A0 (en) * 2009-04-24 2016-01-31 Iceutica Pty Ltd Method for improving the dissolutionprofile of a biologically active material
NZ710384A (en) 2009-04-24 2017-03-31 Iceutica Pty Ltd A novel formulation of indomethacin
JP5909796B2 (ja) * 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
US20150250751A1 (en) * 2012-10-16 2015-09-10 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
US20150246060A1 (en) 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
TWI686212B (zh) * 2013-03-15 2020-03-01 阿聯商太陽法瑪全球有限公司 醋酸阿比特龍配方
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US20180153835A1 (en) * 2015-06-05 2018-06-07 Lupin Limited Compositions of diclofenac acid
CN108697700B (zh) 2016-02-04 2021-08-17 辛多美制药有限公司 氘代多潘立酮组合物和用于治疗病症的方法
US11364226B2 (en) 2017-06-30 2022-06-21 Cinrx Pharma, Llc Deuterated domperidone compositions, methods, and preparation
CN106267209A (zh) * 2016-07-18 2017-01-04 苏州朗易生物医药研究有限公司 低剂量非甾体抗炎类药物组合物及其制备工艺
EP3538071B1 (en) 2016-11-10 2022-09-14 Medisca Pharmaceutique Inc. Pharmaceutical compounding methods and systems
CN106580886A (zh) * 2016-12-05 2017-04-26 北京万全德众医药生物技术有限公司 一种双氯芬酸钾散剂及其制备方法
CA3061267A1 (en) * 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
US12478612B2 (en) 2017-06-30 2025-11-25 Cindome Pharma, Inc. Deuterated domperidone compositions, methods, and preparation
WO2019030773A1 (en) * 2017-08-10 2019-02-14 Sarudbhava Formulations Private Limited DICLOFENAC COMPOSITIONS WITH LOW DOSE
KR20220007198A (ko) 2020-07-10 2022-01-18 오훈 골프장의 홀컵 교체를 위한 홀 가공장치 및 그 홀의 시공방법
CN114088624B (zh) * 2021-11-09 2022-08-26 北京中检葆泰生物技术有限公司 用于谷物颗粒表面规则度检测设备
CN115317464B (zh) * 2022-09-01 2023-08-08 苏州弘森药业股份有限公司 一种双氯芬酸钾微胶囊及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
IT1286778B1 (it) * 1996-11-20 1998-07-17 Alfa Wassermann Spa Capsule contenenti diclofenac o suoi sali in soluzione
AU6853498A (en) * 1997-04-22 1998-11-13 Nippon Kayaku Kabushiki Kaisha Flutamide preparations and method for manufacturing the same
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
CA2420597C (en) 2000-08-31 2011-05-17 Rtp Pharma Inc. Milled particles
JP2005508939A (ja) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル,リミティド 即時放出および徐放特性を組み合わせて有する組成物
US9101540B2 (en) 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
GB0320522D0 (en) 2003-09-02 2003-10-01 Glaxo Group Ltd Formulation
UA89513C2 (uk) 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JP2008524239A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
CA2858733C (en) * 2004-12-31 2017-12-19 Iceutica Pty Ltd Nanoparticle compositions and methods for synthesis thereof
US20060204588A1 (en) 2005-03-10 2006-09-14 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
WO2006116596A2 (en) 2005-04-28 2006-11-02 Wyeth Micronized tanaproget and compostions containing same
JO3352B1 (ar) * 2005-06-17 2019-03-13 Apr Applied Pharma Res Sa صيغ دايكلوفيناك وطرق استخدامه
CA2631494A1 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
US20070178166A1 (en) * 2005-12-15 2007-08-02 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
NZ573823A (en) 2006-06-30 2012-05-25 Iceutica Pty Ltd Methods for the preparation of biologically active compounds in nanoparticulate form
CA2759123C (en) 2009-04-24 2019-01-15 Iceutica Pty Ltd Compositions of diclofenac acid with improved dissolution

Also Published As

Publication number Publication date
EA201171285A1 (ru) 2012-05-30
CA2759123C (en) 2019-01-15
US8679544B2 (en) 2014-03-25
NZ620887A (en) 2015-08-28
EP2421525A1 (en) 2012-02-29
JP2012524723A (ja) 2012-10-18
EP3290030A1 (en) 2018-03-07
BRPI1014272A2 (pt) 2016-10-18
US9186328B2 (en) 2015-11-17
CN106727477A (zh) 2017-05-31
DK2421525T3 (en) 2017-09-25
US20140220121A1 (en) 2014-08-07
IL215869B (en) 2019-02-28
MA33295B1 (fr) 2012-05-02
AP2015008933A0 (en) 2015-12-31
AU2010239080B2 (en) 2014-08-28
CN102438610A (zh) 2012-05-02
AU2010239080A1 (en) 2011-11-10
US9180095B2 (en) 2015-11-10
US9173854B2 (en) 2015-11-03
MY168079A (en) 2018-10-11
SG175314A1 (en) 2011-11-28
US20180296514A1 (en) 2018-10-18
US20160067199A1 (en) 2016-03-10
EP2421525A4 (en) 2013-01-23
JP6154846B2 (ja) 2017-06-28
EP2421525B1 (en) 2017-06-07
TN2011000543A1 (en) 2013-05-24
IL215869A0 (en) 2012-01-31
MX337619B (es) 2016-03-10
CN106420667A (zh) 2017-02-22
PH12015500301A1 (en) 2015-12-07
PH12015500301B1 (en) 2015-12-07
US20160058707A1 (en) 2016-03-03
HK1202061A1 (en) 2015-09-18
MX347290B (es) 2017-04-17
HK1231383A1 (zh) 2017-12-22
JP6222924B2 (ja) 2017-11-01
US8735450B2 (en) 2014-05-27
AP3774A (en) 2016-08-31
US20150157573A1 (en) 2015-06-11
CN104161743A (zh) 2014-11-26
MX2011011222A (es) 2012-02-08
US20150150823A1 (en) 2015-06-04
ZA201108650B (en) 2013-01-30
US20120135047A1 (en) 2012-05-31
US8999387B2 (en) 2015-04-07
US20150150824A1 (en) 2015-06-04
NZ595987A (en) 2014-02-28
US20130209569A1 (en) 2013-08-15
US20170100356A1 (en) 2017-04-13
KR20120029398A (ko) 2012-03-26
JP2015157851A (ja) 2015-09-03
KR101580656B1 (ko) 2015-12-30
US20140248359A1 (en) 2014-09-04
AP2011005989A0 (en) 2011-12-31
US9017721B2 (en) 2015-04-28
SG10201401700XA (en) 2014-06-27
US9180096B2 (en) 2015-11-10
US20150150805A1 (en) 2015-06-04
WO2010121327A1 (en) 2010-10-28
NZ710383A (en) 2017-04-28
KR20140124873A (ko) 2014-10-27
KR20150086563A (ko) 2015-07-28
CO6470810A2 (es) 2012-06-29
KR20170002683A (ko) 2017-01-06
UA106232C2 (uk) 2014-08-11
CA2759123A1 (en) 2010-10-28
CN106727424A (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
JP6177275B2 (ja) ナプロキセンの新規製剤
US20210403442A1 (en) Novel formulation of metaxalone
KR101580656B1 (ko) 디클로페낙의 신규 제형
KR101824831B1 (ko) 신규 멜록시캄 제제
AU2015261687A1 (en) A Novel Formulation of Naproxen
AU2014201967B2 (en) A Novel Formulation of Naproxen

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150129

Application number text: 1020117027888

Filing date: 20111122

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150402

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150611

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150611

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I